Dtsch Med Wochenschr 2004; 129(33): 1743-1746
DOI: 10.1055/s-2004-829026
Aktuelle Diagnostik & Therapie
Neurologie / Immunologie
© Georg Thieme Verlag Stuttgart · New York

Paraneoplastische neurologische Autoimmunerkrankungen

Paraneoplastic neurological autoimmune diseases R. Voltz1
  • 1Institut für Klinische Neuroimmunologie, Klinikum Großhadern, München
Further Information

Publication History

eingereicht: 30.4.2004

akzeptiert: 22.7.2004

Publication Date:
05 August 2004 (online)

Glossar

anti-VGCC = Antikörper gegen spannungsabhängige Ca-Kanäle

CRMP5/CV2-Antikörper = Antikörper gegen „Collapsin response mediator Protein”

EEG = Elektro-Enzephalogramm

FDG-PET = Positronenemissions-Tomographie mit Fluor-Deoxyglukose

Hu-Antikörper = benannt nach dem Index-Patienten Hull

LEMS = Lambert-Eaton-Myastheniesyndrom

LP = Lumbalpunktion

Ma-/Ta-Antikörper = benannt nach der Indexpatientin Taylor

MRT = Magnetresonanz-Tomographie

PKD = Paraneoplastische Kleinhirndegeneration

PLE = Paraneoplastische limbische Enzephalitis

PNS Euronetwork = Paraneoplastic neurological syndromes Euro- network

SCLC = kleinzelliges Bronchial-Karzinom

SN = sensible Neuronopathie

Yo-Antikörper = benannt nach der Index-Patientin Young

Literatur

  • 1 Bain P G, Motomura M, Newsom-Davis J. et al . Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome.  Neurology. 1996;  47 678-683
  • 2 Dalmau J, Gultekin S H, Voltz R. et al . Ma1, a novel neuronal and testis specific protein, is recognized by the serum of patients with paraneoplastic neurologic disorders.  Brain. 1999;  122 27-39
  • 3 Darnell R B, Posner J B. Paraneoplastic syndromes involving the nervous system.  N Engl J Med. 2003;  349 1543-1554
  • 4 Graus F, Cordon-Cardo C, Posner J B. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer.  Neurology. 1985;  35 538-543
  • 5 Graus F, Dalmau J, Rene R. et al . Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to the therapy and improved survival.  J Clin Oncol. 1997;  15 2866-2872
  • 6 Graus F, Delattre J Y, Antoine J C, Dalmau J, Giometto B, Grisold W, Honnorat J, Sillevis S mitt P, Vedeler C, Verschuuren J, Vincent A, Voltz R. for the Paraneoplastic Neurological Syndrome Euronetwork . Recommended diagnostic criteria for paraneoplastic neurological syndromes.  J Neurol Neurosurg Psychiatry. 2004;  in Druck
  • 7 Graus F, Keime-Guibert F, Rene R. et al . Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.  Brain. 2001;  124 1138-1148
  • 8 Gultekin S H, Rosenfeld M R, Voltz R. et al . Paraneoplastic limbic encephalitis: tumor association, neurological symptoms, and immunological findings in 50 patients.  Brain. 2000;  123 1481-1494
  • 9 Honnorat J, Antoine J C, Derrington E. et al . Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.  J Neurol Neurosurg Psychiatry. 1996;  61 270-278
  • 10 Linke R, Schröder M, Helmberger Th, Voltz R. Antibody-positive paraneoplastic neurological syndromes: The value of CT and FDG-PET imaging for tumor diagnosis.  Neurology. 2004;  63 282-286
  • 11 Maddison P, Newsom-Davis J, Mills K R, Souhami R L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.  Lancet. 1999;  353 117-118
  • 12 Mason W P, Graus F, Lang B. et al . Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.  Brain. 1997;  120 1279-1300
  • 13 Molinuevo J L, Graus F, Serrano C. et al . Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy.  Ann Neurol. 1998;  44 976-980
  • 14 Posner J B. Paraneoplastic syndromes. Contemporary Neurological Series, FA Davis In: Posner JB. Neurologic complications of cancer 1995: 353-385
  • 15 Rojas I, Graus F, Keime-Guibert F. et al . Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.  Neurology. 2000;  55 713-715
  • 16 Rosenfeld M R, Eichen J G, Wade D F. et al . Molecular and clinical diversity in paraneoplastic immunity to Ma proteins.  Ann Neurol. 2001;  50 339-348
  • 17 Voltz R, Carpentier A F, Rosenfeld M R. et al . P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system.  Muscle Nerve. 1999;  22 119-122
  • 18 Voltz R, Gultekin S H, Rosenfeld M R. et al . A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.  N Engl J Med. 1999;  340 1788-1795
  • 19 Voltz R. Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis and therapy.  The Lancet Neurology. 2002;  1 294-305
  • 20 Yu Z, Kryzer T J, Griesmann G E. et al . CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.  Ann Neurol. 2001;  49 146-154

Prof. Dr. Raymond Voltz

Institut für Klinische Neuroimmunologie, Klinikum Großhadern

81366 München

Phone: 089/70954439 oder -0,

Fax: 089/70957435 oder -4782

Email: rvoltz@nro.med.uni-muenchen.de

    >